By Denny Jacob
Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.
The medical technology company said the regulator approved BrainSense Adaptive deep brain stimulation and BrainSense Electrode Identifier. It added that they offer therapy personalization for symptom control that automatically adjusts to a patient's needs.
Medtronic said both BrainSense offerings are available in Europe. Patient programmings in the U.S. will begin at select healthcare systems over the coming weeks with availability nationwide in the coming months, it added.
Parkinson's occurs when cells deep in the brain that produce dopamine, which coordinates movement, become impaired or die. Symptoms include tremors, stiffness, slow movements and problems with balance.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
February 24, 2025 09:28 ET (14:28 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。